Pathophysiologyof hypertrophic cardiomyopathy

Lancet

Volumn 355, Issue 9207, 2000, Pages 928-

  Östman Smith, Ingegerd ^a   Wettrell, Göran ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INSULIN; SOMATOMEDIN C;

ADRENERGIC SYSTEM; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INFANT; LETTER; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0034635888     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)74130-1     Document Type: Letter

References (5)

1. AJ Marian Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 355 2000 58 60
2. I Östman-Smith Cardiac sympathetic nerves as the final common pathway in the induction of adaptive cardiac hypertrophy. Clin Sci 61 1981 265 272
3. JE Brush G Eisenhofer M Garty Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 79 1989 835 844
4. I Östman-Smith G Wetrell Benefit from high-dose β-blocker therapy on survival and morbidity in childhood hyprtrophic cariomyopathy. Imai Y Momma K Proceedings of the second world congress of paediatric cardiology and cardiac surgery. 1998 Futura Publishing New York 241 244
5. I Östman-Smith G Wettrell T Riesenfeld A cohort study of childhood hypertrophic cardiomyopathy: improved survival followig his-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 34 1999 1813 1822